CU20190022A7 - Composición farmacéutica para el tratamiento de la úlcera del pie diabético - Google Patents
Composición farmacéutica para el tratamiento de la úlcera del pie diabéticoInfo
- Publication number
- CU20190022A7 CU20190022A7 CU2019000022A CU20190022A CU20190022A7 CU 20190022 A7 CU20190022 A7 CU 20190022A7 CU 2019000022 A CU2019000022 A CU 2019000022A CU 20190022 A CU20190022 A CU 20190022A CU 20190022 A7 CU20190022 A7 CU 20190022A7
- Authority
- CU
- Cuba
- Prior art keywords
- treatment
- pharmaceutical composition
- diabetic foot
- foot ulcer
- ulcer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
<p>La presente invención provee una composición farmacéutica que comprende factor de crecimiento epidérmico (FCE), para el tratamiento de la úlcera de pie diabético (UPD) en un paciente sin criterio de amputación del miembro afectado al momento de la evaluación, donde la composición se administra una vez por semana, por infiltración intralesional en el lecho de dicha úlcera. Junto al FCE, la composición comprende excipientes aceptados farmacéuticamente.</p> <p> </p>
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2019000022A CU20190022A7 (es) | 2019-03-18 | 2019-03-18 | Composición farmacéutica para el tratamiento de la úlcera del pie diabético |
US17/440,698 US20220168391A1 (en) | 2019-03-18 | 2020-03-16 | Use of epidermal growth factor in diabetic foot ulcer treatment |
AU2020242803A AU2020242803A1 (en) | 2019-03-18 | 2020-03-16 | Use of epidermal growth factor in diabetic foot ulcer treatment |
CA3133755A CA3133755A1 (en) | 2019-03-18 | 2020-03-16 | Use of epidermal growth factor in diabetic foot ulcer treatment |
MX2021011336A MX2021011336A (es) | 2019-03-18 | 2020-03-16 | Uso del factor de crecimiento epidermico en el tratamiento de la ulcera del pie diabetico. |
EP20757210.8A EP3936146A1 (en) | 2019-03-18 | 2020-03-16 | Use of epidermal growth factor in diabetic foot ulcer treatment |
PCT/CU2020/050003 WO2020187341A1 (es) | 2019-03-18 | 2020-03-16 | Uso del factor de crecimiento epidermico en el tratamiento de la ulcera del pie diabetico |
BR112021018323A BR112021018323A2 (pt) | 2019-03-18 | 2020-03-16 | Uso do fator de crescimento epidérmico no tratamento da úlcera de pé diabético |
JP2021556518A JP2022525935A (ja) | 2019-03-18 | 2020-03-16 | 糖尿病性足部潰瘍の治療における上皮細胞増殖因子の使用 |
CN202080030986.0A CN113727727A (zh) | 2019-03-18 | 2020-03-16 | 表皮生长因子在治疗糖尿病性足溃疡中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2019000022A CU20190022A7 (es) | 2019-03-18 | 2019-03-18 | Composición farmacéutica para el tratamiento de la úlcera del pie diabético |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20190022A7 true CU20190022A7 (es) | 2020-10-20 |
Family
ID=72087853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2019000022A CU20190022A7 (es) | 2019-03-18 | 2019-03-18 | Composición farmacéutica para el tratamiento de la úlcera del pie diabético |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220168391A1 (es) |
EP (1) | EP3936146A1 (es) |
JP (1) | JP2022525935A (es) |
CN (1) | CN113727727A (es) |
AU (1) | AU2020242803A1 (es) |
BR (1) | BR112021018323A2 (es) |
CA (1) | CA3133755A1 (es) |
CU (1) | CU20190022A7 (es) |
MX (1) | MX2021011336A (es) |
WO (1) | WO2020187341A1 (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HK1077740A1 (en) * | 2001-12-20 | 2006-02-24 | Ct Ingenieria Genetica Biotech | Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation |
CU23388B6 (es) * | 2006-01-31 | 2009-07-16 | Ct Ingenieria Genetica Biotech | Composición farmacéutica de microesferas para prevenir la amputación del pie diabético |
CU24121B1 (es) * | 2012-08-02 | 2015-08-27 | Ct De Ingeniería Genética Y Biotecnología | Vesículas que comprenden factor de crecimiento epidérmico y composiciones que las contienen |
EP2737895A1 (en) * | 2012-11-30 | 2014-06-04 | Praxis Pharmaceutical, S.A. | Microparticles with EGF, method of preparation and use |
-
2019
- 2019-03-18 CU CU2019000022A patent/CU20190022A7/es unknown
-
2020
- 2020-03-16 JP JP2021556518A patent/JP2022525935A/ja active Pending
- 2020-03-16 BR BR112021018323A patent/BR112021018323A2/pt unknown
- 2020-03-16 AU AU2020242803A patent/AU2020242803A1/en active Pending
- 2020-03-16 EP EP20757210.8A patent/EP3936146A1/en active Pending
- 2020-03-16 MX MX2021011336A patent/MX2021011336A/es unknown
- 2020-03-16 WO PCT/CU2020/050003 patent/WO2020187341A1/es unknown
- 2020-03-16 CN CN202080030986.0A patent/CN113727727A/zh active Pending
- 2020-03-16 CA CA3133755A patent/CA3133755A1/en active Pending
- 2020-03-16 US US17/440,698 patent/US20220168391A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112021018323A2 (pt) | 2021-11-23 |
WO2020187341A1 (es) | 2020-09-24 |
CN113727727A (zh) | 2021-11-30 |
JP2022525935A (ja) | 2022-05-20 |
AU2020242803A1 (en) | 2021-10-14 |
MX2021011336A (es) | 2021-10-13 |
US20220168391A1 (en) | 2022-06-02 |
EP3936146A1 (en) | 2022-01-12 |
CA3133755A1 (en) | 2020-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891606A1 (ru) | Композиции и способы для внутривенного введения 2-бром-1-(3,3-динитроазетидин-1-ил)этанона | |
EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
BRPI0917315B8 (pt) | anticorpo monoclonal, seu uso e composição farmacêutica o compreendendo | |
CL2019002270A1 (es) | Conjugados de anticuerpo y fármaco anti-egfr. (divisional solicitud 201803527) | |
CY1105202T1 (el) | Διασπειρομενες φαρμακευτικες συνθεσεις | |
BR112021022335A2 (pt) | Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer | |
CL2021003141A1 (es) | Uso de una composición para el cuidado bucal. | |
PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
CL2017000494A1 (es) | Tratamientos médicos a base de anamorelina. | |
CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
CO2018000768A2 (es) | Administración intravenosa de citrulina durante la cirugía | |
CU20190022A7 (es) | Composición farmacéutica para el tratamiento de la úlcera del pie diabético | |
PE20210123A1 (es) | Compuesto de anillo de metillactama y uso farmaceutico del mismo | |
RU2013153030A (ru) | Способ введения лекарственного препарата на постоперационную рану при непосредственном зубном или челюстном протезировании | |
EA201791895A1 (ru) | Дозы и способы введения телаванцина | |
PH12018501769A1 (en) | Medicament for treatment of diabetic foot infections | |
MX2021014803A (es) | Anticuerpo anti-factor de crecimiento de tejido conectivo y aplicacion del mismo. | |
EA202190614A1 (ru) | Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря | |
EA202192483A1 (ru) | Лекарственное средство и способ лечения или профилактики осложнений диабета с использованием этого лекарственного средства | |
AR083337A1 (es) | Tratamientos de infeccion por el virus de hepatitis c | |
CL2022001079A1 (es) | Métodos y composiciones para el tratamiento del síndrome de rett | |
EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação |